Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Dreyling, Martin (author)

Jurczak, Wojciech (author)

Jerkeman, Mats (author)

Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund

show more...

Silva, Rodrigo Santucci (author)

Rusconi, Chiara (author)

Trneny, Marek (author)

Offner, Fritz (author)

Caballero, Dolores (author)

Joao, Cristina (author)

Witzens-Harig, Mathias (author)

Hess, Georg (author)

Bence-Bruckler, Isabelle (author)

Cho, Seok-Goo (author)

Bothos, John (author)

Goldberg, Jenna D (author)

Enny, Christopher (author)

Traina, Shana (author)

Balasubramanian, Sriram (author)

Bandyopadhyay, Nibedita (author)

Sun, Steven (author)

Vermeulen, Jessica (author)

Rizo, Aleksandra (author)

Rule, Simon (author)

show less...

 (creator_code:org_t)

2016

2016

English.

In: The Lancet. - 1474-547X. ; 387:10020, s. 770-778

Related links:

http://www.ncbi.nlm....

show more...

http://dx.doi.org/10...

https://lup.lub.lu.s...

https://doi.org/10.1...

show less...

• Journal article (peer-reviewed)